Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 1 Oct 2016

Arends J E, Kracht P A M, Hoepelman A I M

Abstract excerpt

In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48 weeks with limited success to all-oral single tablet regimens taken for 12 weeks with very high chances of success. These promising results are not available to everybody. Depending on, for example, geographical factors with limited availability of new compounds,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Liver Cirrhosis

Share to Treatment Outcome

Source

Identifiers

PMID: 27297320
DOI: 10.1016/j.cmi.2016.05.027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice.PMID 27297320Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

Advances in hepatitis C therapies.Semantic proximity Read ↗

Update on hepatitis C treatment: systematic review of clinical trials.Semantic proximity Read ↗

Novel therapies for hepatitis C - one pill fits all?Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

What does the pharmacological future of treating chronic hepatitis C look like?Semantic proximity Read ↗

New hepatitis C therapies: the toolbox, strategies, and challenges.Semantic proximity Read ↗

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.Semantic proximity Read ↗

Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center.Semantic proximity Read ↗

Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.